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Abstract (247 words) 
Aims: The EuroHeart Failure Survey Questionnaire (EHFSQ-1) has 39 questions on 
symptoms and quality of life (QoL); many items are related. We sought to identify 
underlying clusters amongst EHFSQ-1 questions, construct an overall “QoL score” 
and investigate its relationship to a single question asking patients to self-rate QoL. 
Methods and results: Factor analysis based on the principal component technique 
was used to identify patterns amongst responses to QoL questions from patients 
referred with symptoms suggesting heart failure (HF). Of 1031 patients, median age 
71 (IQR: 63-77) years, 64% were men and 626 had confirmed HF. For patients with 
HF, seven symptom-clusters were identified: “breathlessness”, “psychological 
distress”, “sleep quality”, “frailty”, “cognitive/psychomotor function”, “cough” and 
“chest pain”. These clusters accounted for 65% of the total variance in QoL score. 
Cluster pattern was similar in patients with and without HF. A summary factor score 
was tightly correlated with summary QoL score (correlation coefficient: r=0.96; 
p<0.0001). Both summary factors and QoL scores were highly correlated with patient 
self-rating of overall health (r1=0.61 and r2=0.66 respectively, p<0.0001) or overall 
QoL (r1=0.60 and r2=0.66, p<0.0001). The medians (IQR) of the summary QoL score 
for patients with HFrEF, HFnEF and no-HF were, respectively, 83 (60-106), 82 (59-
104) and 71 (51-94). 
Conclusions: EHFSQ-1, comprises seven symptom clusters in patients with HF. 
Either summary factors or QoL scores can be used as a QoL outcome measure. 
However, if the key question is „what is this patient‟s QoL?‟ rather than the reason 
why it is impaired, then a single, direct question may suffice. 
Key words: Patterns of quality of life; suspected heart failure; left ventricular systolic 
dysfunction 
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Introduction 
The goals of treating heart failure are to maintain or improve the quality of life by 
managing symptoms and reducing morbidity and disability and to prolong useful life. 
Ultimately, improving the „patient journey‟ [1] or quality-adjusted life-years is the 
objective of both patients and their doctors. However, most clinical trials of heart 
failure focus on morbidity and mortality rather than on quality of life (QoL), which is 
usually measured infrequently during the course of the trial, if at all. This partly 
reflects a lack of confidence amongst both trialists and regulators about the validity of 
tools used to assess QoL and partly the perceived burden on both patients and 
investigators of completing existing QoL questionnaires repetitively. However, QoL 
questionnaires are asking two distinct questions; firstly “what is this patient‟s QoL?” 
and secondly, “if impaired, „why‟?”. However, in a clinical trial the first question may 
be of greater importance. The second may give insights into how an intervention has 
changed QoL but with few exceptions [2], this is never reported in trials. This issue 
could be addressed if investigators and regulators were willing to accept that the 
patient is the best judge of their QoL which could reduce the complexity of 
assessment of QoL to a single question that could be asked at every visit. This would 
permit the calculation of average QoL throughout the study as well as an assessment 
of the impact of morbid events on QoL. Trying to measure QoL using questionnaires 
is not straightforward. Inevitably, questionnaires concentrate on symptoms thought to 
be important by clinicians, but not necessarily patients, and include a large number of 
questions that are often highly related. Factor analysis (FA) [3,4] reduces complex 
information by identifying latent structures in the data and extracting highly correlated 
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sets of symptoms as “symptom clusters”. Each symptom cluster can be scored and 
used for further analysis [5,6]. 
The aim of the present study was to identify symptom clusters in the EuroHeart 
Failure Survey Questionnaire used in the first survey (EHFSQ-1), to construct an 
overall “QoL score” from them and then to relate this score to patient self-reported 
QoL using single questions [7,8] using data acquired routinely as part of a clinical 
heart failure service. 
Methods 
Patients referred to a community heart failure clinic (Kingston-upon-Hull, UK) for the 
assessment of heart failure symptoms were invited to participate. Patients underwent 
clinical examination, including demographic measurements, symptoms and signs, 
electrocardiograms, echocardiography and routine haematology and biochemical 
investigations. The questionnaire was designed by a group of experts to obtain data on 
symptom severity and quality of life in the first EuroHeart Failure survey. It has not, 
as far as we are aware, been subjected to detailed methodological validation. 
Patients were sent the EuroHeart Failure Survey Questionnaire (EHFSQ-1), which 
comprises 39 questions (Table 2.1 and 2.2), in the post prior to attending the clinic. 
No restriction was placed on seeking the advice and opinion of friends and relatives. 
The first 37 questions (1-37) ask about specific symptoms. The response to each 
question could be: no, very little, a little, some, a lot, very much, unknown and was 
coded from 1 to 6; unknown was coded as 7 and was excluded in this study. The 
following four questions (18-21) were very often left unanswered: inability to work 
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due to your health; side effects that you think might be due to your treatment; 
difficulties with sexual function; and cost of medicines or medical care. They were 
excluded for the purposes of this analysis. The final two questions (38-39) ask about 
general health, and overall quality of life. Each could be answered: very good, good, 
quite good, average, quite poor, poor, very poor and unknown. The responses to both 
questions were coded from 1 to 7; unknown was coded as 8 and was excluded in the 
study 
All patients provided written informed consent for their data to be used and the study 
was carried out in accordance with the Helsinki Declaration II and the European 
Standards for Good Clinical Practice. Ethical approval was granted by the Hull and 
East Yorkshire Local Research Ethics Committee. 
Patients were enrolled at first assessment in an out-patient clinic and all had a history 
suspicious of heart failure or concerns about important  cardiac dysfunction. In the 
context of the sort of patients referred, heart failure was defined as being present if the 
left ventricular ejection fraction (LVEF) was less than 40% (heart failure with reduced 
ejection fraction; HFrEF) or, if LVEF was ≥ 40%, by an NT-proBNP >400ng/L (heart 
failure with normal ejection fraction; HFnEF). Patients who had both LVEF >40% 
and NT-proBNP <400ng/L were considered not to have heart failure for the purposes 
of this analysis, although other thresholds and criteria were considered. 
Statistical analysis 
Continuous variables are expressed as a median with inter quartile range; and 
categorical variables are given as percentages. Differences between the groups were 
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examined using independent t-test or Mann-Whitney U test and chi-square tests for 
continuous and categorical variables respectively. Pearson‟s correlation coefficient 
and Spearman‟s correlation coefficient with scatter plots were used to assess the 
correlations or relationships between two variables depending on the distribution of 
the data. 
Exploratory factor analysis (FA) was performed using principal component analysis 
(PCA). PCA is a data reduction technique which transforms a number of correlated 
variables into a smaller number of uncorrelated variables termed principal 
components (that is, linear combinations of the original variables) which explain a 
large proportion of the original sample variance. The 4 questions 18-21 mentioned 
above were not included in the analysis due to too many missing values and general 
overall QoL and overall health were not included. The remaining 33 questions were 
considered in the analysis. 
To identify QoL symptom clusters, only principal components with initial eigenvalues 
>1 were extracted and an orthogonal factor rotation with Varimax method [9] applied. 
The symptom clusters were labelled according to the characteristics of the original 
variables. Variables with a factor loading >0.4 were considered to be an important 
component of an underlying symptom cluster (Factor loading is a correlation between 
a variable and a factor. The higher the load the more relevant in defining the factor.). 
Symptom cluster scores were calculated based on the Anderson-Rubin method
 
[10] 
for further analysis. The sampling adequacy was checked by the Kaiser-Meyer-Olkin 
(KMO) test [11]. The 10-fold cross-validation was used to assess the stability of the 
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analysis and Cronbach's alpha
 
[12] was used for testing the reliability of questions on 
each symptom cluster. 
Overall QoL scores were derived using either (1) the raw summary scores (ranging 
potentially from 31 (very good health) to 186 (terrible health)); or (2) the summary 
factor scores derived by the sum of each symptom cluster score, ranging from -5 to 10 
in this dataset (a big number is associated with a bad health).
Statistical analysis was carried out using SPSS 17 software package. The two-tailed 
level of statistical significance was set at p<0.05. 
Results 
Baseline characteristics 
Of 1,031 patients, 657 (64%) were men and the median age was 71 years (IQR: 63-
77), 626 had HF (377 with HFrEF and 249 with HFnEF) and 405 did not fulfil the 
criteria for HF (Table 1). As expected, patients with HF had more severe symptoms, 
more cardiovascular problems, poorer renal function and substantially higher plasma 
concentrations of NT-proBNP despite receiving more loop diuretics, ACE inhibitors, 
beta blockers and spironolactone. Patients with HFnEF were older, more often women 
and had more atrial fibrillation and diabetes. BMI was greater in patients without 
heart failure but the rate of reported COPD was similar in each group. 
The distributions of the responses of QoL questions for patients with HFrEF, HFnEF 
or No HF are shown in Table 2. This showed a broadly similar pattern in patients with 
different heart failure phenotypes. There was also an extensive overlap in 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Exploring Quality of Life in Heart Failure 
Page 8 of 20 
symptomatology between patients who were considered to have or not have heart 
failure. For instance, 15.7% of patients with HFrEF reported ankle swelling in the 
worst two ranks, compared to 22.8% of those with HFnEF and 17.5% of those 
without heart failure. Reports of severe breathlessness at rest were uncommon in this 
out-patient population and rare in patients without heart failure. For breathlessness 
during daily activity, 34.7% of patients with HFrEF reported scores in the worst two 
ranks, compared to 37.0% of those with HFnEF and 21.3% of those without heart 
failure. Fatigue during daily activity was reported in the worst two ranks in 26.8%, 
27.7% and 16.3% of the above groups, respectively. Patients scoring chest pain in the 
worst two ranks were similar across diagnostic groups but patients without heart 
failure complained more of troublesome cough. The medians (IQR) of the summary 
QoL scores with IQRs for patients with HFrEF, HFnEF and no-HF were, respectively, 
83 (60-106), 82 (59-104) and 71 (51-94). Of those that did not fulfil the criteria for 
HF, the scores were 85 (69-111) and 64 (48-85) for those taking or not taking loop 
diuretics and 72 (56-99) and 68 (47-89) above and below an NT-proBNP of 125ng/L. 
Patterns of QoL 
In the initial factor analysis 33 questions were considered. However, indigestion and 
SoA variables were removed from final FA because of small values of the 
communalities (<0.35) (the communality is the proportion of variation in the variable 
explained by all the symptom clusters). There were seven underlying QoL symptom 
clusters extracted from the 31 variables explained 65% of total variance. Factor 
loadings >0.4 were shown and important factor loadings >=0.7 were bolded (Table 3). 
The KMO test measuring the sampling adequacy was 0.929; values >0.5 indicate that 
the sample size is appropriate for FA. Bartlett‟s test of sphericity showed that the 
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correlations between items were sufficiently large for PCA (chi-square=10273, df = 
465 and p<0.001). Cronbach's alpha showed a range of scores from 0.62 to 0.89 and 
five of seven scores had values >0.7, which indicates that the questionnaire has 
satisfactory internal reliability [13,14]. 
 
The following seven symptom clusters were extracted in patients with HF (Table 3): 
1. The first cluster called “Breathlessness” accounted for 15% of the total variance in 
QoL. The cluster Breathlessness was highly related to: inability to do normal daily 
activities with the factor loading 0.78, fatigue on daily activities (0.76), breathless 
limiting normal daily activities (0.75) and reduced ability to pursue hobbies (0.73). 
That is the cluster was mainly loaded by these questions.  
 
2. The second cluster called “Psychological distress” including stress, depression and 
anxiety accounted for 13% of the total variance.  
 
3. “Sleep quality” including insomnia, waking and lack of refreshing sleep accounted 
for 9% of the total variance.  
 
4. “Frailty” included questions relating to making you stay in hospital, eating less 
food, finding going places away from home difficult and the need for stays in hospital 
accounted for 8% of the total variance.  
 
5. “Cognitive/Psychomotor impairment” (loss of memory, falls, dizziness, and 
muscles) accounted for 8% of the total variance. 
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6. “Respiratory symptoms” (cough, wheeze and breathless at night) accounted for 6% 
of the total variance. 
 
7. “Chest pain” (chest pain at rest, chest pain at daily activity) were also extracted 
accounted for 6% of the total variance.  
 
A 10-fold cross-validation for patients with HF was used and revealed the stability of 
the analysis (result was not shown. It can be found from on-line supplement). 
 
Amongst patients who did not have heart failure, an 8
th
 symptom cluster, “falls”, was 
identified, with the 8 clusters accounting for 66% of total variance (see Table 3). 
Muscle aches and indigestion were not included in the final analysis due to small 
values of the communalities.  The KMO test (0.919) for this group shows that the 
sample size was adequate. The components and the order in which they entered the 
symptom clusters, was slightly different from the patients with heart failure: patients 
with HF had clearer and more specific patterns than those without HF. 
 
Relationships between single symptom scores and general overall QoL and 
overall health 
There was a strong positive correlation between the summary QoL and the summary 
symptom cluster scores for both patients with and without HF (Pearson‟s correlation 
coefficient: r = 0.964/0.954 respectively with p<0.001, Figure 1 and Table 4.1). There 
was a strong relationship between two individual questions on „overall health‟ and 
„overall QoL‟ (Spearman‟s correlation coefficient:  r´ = 0.730/0.759 for patients 
with/without HF respectively, p<0.001). There were also strong relationships between 
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overall health/overall QoL with the summary score and the summary symptom cluster 
score (r´= (0.661, 0.614) / (0.658, 0.602) respectively with p<0.001 for HF patients; 
and r´= (0.667, 0.678) / (0.642, 0.654) respectively with p<0.001 for no HF patients). 
Only the first symptom cluster (“Breathlessness”) was highly related to the single 
questions on „overall QoL‟ and „overall health‟ (r´=0.50 and 0.47 respectively, 
p<0.001 for all; Table 4.2) in patients with HF.  
 
Relationships between QoL scores with NYHA class and NT-proBNP 
On average, patients without heart failure had lower summary scores, and lower 
scores in response to single questions on overall QoL and overall health scores than 
patients with heart failure represented as NYHA class II/III/IV. QoL scores increased 
(worsened) as NYHA class deteriorated (Figure 2.1); and in general QoL scores 
worsened as NT-proBNP increased, especially in patients with AF (Figure 2.2).  
 
Discussion 
This analysis suggests that when the main question of interest is simply “what is the 
patient‟s quality of life”, then asking the patients to rate it directly using a single 
question may be sufficient or perhaps superior to asking a series of related questions 
that skirt the issue, as is the case with QoL questionnaires. Use of a single question to 
assess QoL could greatly increase the acquisition of QoL data in clinical trials. Rather 
than being measured at infrequent intervals or not at all, it could become a standard 
part of every assessment. QoL is unlikely to be stable over long-periods of time in 
patients with heart failure. It will decline with progression of heart failure or due to 
intercurrent illness and, hopefully, improve with treatment. Acquiring more frequent 
information allows the relationship between events and interventions to be explored 
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more effectively. However, a single question may not be the optimal method of 
assessing QoL in a clinical trial when used alone. A mixed approach, with frequent 
use of a single-question supported periodically by more detailed QoL questionnaires 
would provide a high density of information about QoL combined with insights about 
why it might be imperfect. Further research is required to identify whether the single 
question approach we used is the optimal method of patient self-rating or whether 
other approaches such as visual analogue scales might be better. 
 
The EHFSQ-1 was designed as a tool to capture data on symptoms of heart failure and 
common associated co-morbidities as well as more general aspects of living that 
affect QoL. EHFSQ-1 has not yet been validated as a QoL tool, either in terms of 
reproducibility or in comparison to other QoL instruments such as MLWHFQ 
(MLHFQ [15]) or KCCQ [16]. However, the questions in quality of life 
questionnaires are broadly similar and it is likely that their results are highly 
correlated. Whether KCCQ or MLHFQ is more sensitive to change is a matter of 
debate. EHFSQ-1, with its more extensive set of questions is likely to capture more 
aspects of QoL if the patient completes all the questions. Despite this, the factor 
analysis could explain only about two thirds of the variability in response to a single 
question about QoL. The responses to the two single questions about QoL were highly 
correlated suggesting that the problem may lie with the failure of more complex 
questionnaires to capture information that impinge substantially on and/or deal with 
the heterogeneous factors that affect an individual patient‟s QoL. Interestingly, when 
asked in the context of an out-patient visit, patients did not seem to differentiate 
between general and health-related QoL suggesting that health was the dominant issue 
affecting their QoL. Whether differences would be observed if the questions were 
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asked outside of a healthcare context is unclear and uncertain. Nonetheless, the 
breathlessness symptom cluster score was strongly related to the single questions on 
overall health and overall QoL. Indeed, if these questions were added to the factor 
analysis, they were both incorporated into the breathlessness symptom cluster.  
 
Comparison of patients with and without heart failure shows substantial differences in 
clinical characteristics including age, and co-morbidities as well as cardiac 
dysfunction. There are also differences in symptomatology but these are relatively 
subtle, supporting the notion that diagnosis of heart failure by symptoms alone is 
unreliable. About 80% of patients with heart failure reported that they developed 
some degree of breathlessness during normal daily activity, although this was marked 
in only one third of patients. However, two-thirds of patients without heart failure 
reported some breathlessness during daily activity and this was marked in more than 
20%. Many of these patients had other problems such as obesity, angina, COPD or 
musculo-skeletal problems that could provoke breathlessness and impair QoL. It was 
also possible that some patients were misclassified; the cut-off for NT-proBNP may 
have been too high or diuretics could have concealed features of heart failure. Indeed, 
patients who were not taking diuretics or who had an NT-proBNP <125ng/L had 
better QoL scores. Interestingly, patients taking diuretics that had no other criteria for 
heart failure had similar QoL scores to patients with mild to moderate heart failure, 
suggesting that the diagnostic criteria for heart failure may have been too strict. 
Patients taking loop diuretics are known to have a worse prognosis
 
[17] even if they 
have not been recognized to have heart failure.  
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Amongst patients with heart failure, EHFSQ-1 suggests that functional limitation due 
to breathlessness is a key determinant of QoL. This is not surprising. However, it 
accounted for only 15% of variability of the overall QoL score, which was only 
slightly more than psychological health. Sleep quality, general frailty, cognitive 
function, cough and chest pain made smaller contributions on average but clearly, 
some will have made a substantial contribution in some patients and none at all in 
others. Questionnaires such as EQ5D [18, 19], MLWHFQ, KCCQ and EHFSQ-1 may 
be valuable in determining what has led to an impaired QoL on average or in an 
individual patient. This analysis suggests that EHFSQ-1 might be reduced to seven 
key questions. However, it depends on why the questionnaire is being applied. For 
instance, knowledge about the severity of ankle swelling may be considered important 
for many reasons even if it is not an important determinant of QoL. Thus the complete 
EHFSQ-1 might be used for patient profiling, the seven question version for assessing 
why QoL is impaired and the single question for rating patient-perceived QoL. 
 
There are very few reports on the distribution of symptom scores in questionnaires in 
consecutive patients with heart failure referred for diagnosis and care to a heart failure 
clinic and none on patients with suspected heart failure where the diagnosis was 
refuted. The EHFSQ-1 score was much higher (worse) in patients where the diagnosis 
of heart failure was confirmed and in patients who were in a more severe NYHA 
class. QoL score appeared to be related to NT-proBNP, a marker of the severity of 
cardiac dysfunction and prognosis. Our NT-proBNP threshold for the diagnosis of 
heart failure was based on an interpretation of the 2008 guidelines on heart failure of 
the European Society of Cardiology
 
[20]. Guidelines have since revised the threshold 
downward and it is likely that some patients with HFnEF but well-controlled 
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congestion will have „contaminated‟ the no heart failure group. This sort of problem 
cannot be resolved until a clear and robust definition of HFnEF is agreed. However, 
patients with HFnEF and an NT-proBNP <400ng/L have a much better prognosis than 
those with higher levels. Moreover, there is, as yet, no specific disease-modifying 
therapy for HFnEF and therefore subtle differences in the definition will not alter 
management decisions.  
 
We used principal component analysis (PCA) to extract factors. There is a basic 
difference between factor analysis and PCA. Factor analysis is based on a statistical 
model. It seeks the smallest number of unobserved latent variables (or potential 
factors) that explain the original data. On the other hand, PCA is a transformation, 
which reduces a relatively large number of variables into a small number of 
„principal‟ components  that explain a large proportion of the total sample variance of 
the original variables
5
. However, Rietveld and Van Hout pointed out that  “the 
difference between factor analysis and PCA decreased when the number of variables 
and the magnitudes of the factor loadings increased [21]” and the results of PCA are 
little different from those derived from factor analysis [22].  Exploratory factor 
analysis has the advantages of analysing the structure of data especially when 
correlations between variables are reasonably high and there are a large number of 
variables. Although the method overcomes many of the problems related to analysis 
of a high number of variables many of which are related. 
 
There are some limitations. In EHFSQ-1, four questions related to work, drug side 
effects, costs of care and sexual activities were excluded due to a large number of 
missing values, perhaps reflecting the age of this population and free access to health 
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care provided by the NHS in the UK. Clearly, the EHSQ-1 should be tested for 
reproducibility, sensitivity to change, assessed in additional datasets and healthcare 
settings and compared to other QoL tools. Several such projects are underway. 
However, 10-fold cross-validation has been used to assess the stability of the analysis 
and Cronbach's alpha method has been used for testing the internal consistency of 
questions scores.  
 
In conclusion, for patients with suspected HF, if the aim is to measure QoL it may be 
best just ask the patient a simple question such as „how do you rate your overall 
health?‟ or „how do you rate your overall QoL? Only if it is important to know why a 
patient‟s QoL is less than ideal is it necessary to ask further questions. When QoL is 
being used as an outcome measure then it is usual only to report a summary score or a 
summary symptom cluster score and all the underlying detailed information usually 
goes unreported. Thus, a single question about QoL or patient well-being may suffice 
for most purposes. The greater number and frequency of questions asked the less 
likely they are to be completed. Less is more. 
 
Supplementary material 
Supplementary material is available at International journal of cardiology online. 
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Figure legend 
Figure 1: The correlation between the sum of the seven (or eight for patients without 
heart failure) cluster scores and the sum of scores from the 33 valid individual QoL 
questions  
 
Figure 2.1: The means and the standard deviations: average of raw total score from 
33 questions and patient-rating of overall QoL and overall health using single 
questions for each of NYHA class. Higher values indicate worse QoL 
 
Figure 2.2: Relationship between quintiles of NT-proBNP and different QoL scores 
in patients who were atrial fibrillation (AF) or sinus rhythm (mean with SD within 
each quintile) (The quintiles of NT-proBNP was calculated based on all patients 
regardless of diagnosis or heart rhythm) 
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Figure 1: The correlation between the summary symptom cluster scores and the summary 
scores of QoL questions for all patients (r=0.96, p-value<0.0001) 
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Figure 2.1: The means and the standard deviations of the average raw total QoL score from 33 
questions and patient-rating using single questions of a) overall QoL and b) overall health for each 
NYHA class. Higher values indicate worse QoL. Best possible score for average QoL raw score is 6 and 
for single questions is 7; worst possible score is 1 for the both. 
 No HF and  
no diuretic 
No HF and  
NT-proBNP<125 
No HF NYHA  
class I 
NYHA  
class II 
NYHA  
class III 
NYHA  
class IV 
No. of 
patients  
254 202 405 331 509 179 12 
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  Figure 2.2: Relationship between quintiles of plasma NT-proBNP and QoL scores (mean with SD) in 
patients who were or were not in sinus rhythm (quintiles of NT-proBNP were calculated based on all 
patients regardless of heart rhythm). Heart rhythm is known to have a major effect on plasma NT-
proBNP concentration that might could have affected relationship with symptoms. The following 
table provides the number of patients used in each group. Note the small number of patients with 
AF and NT-proBNP <250ng/L. 
NT-proBNP 
(ng/L) 
Quintile 1 
68 (38-92) 
Quintile 2 
189 (148-249) 
Quintile 3 
548 (415-695) 
Quintile 4 
1403 (1089-1792) 
Quintile 5 
4191 (3048-6952) 
Not SR 6 14 53 92 100 
SR 200 192 153 114 107 
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Supplements: 
 
Figure 1: Loading of first factor (“breathlessness”) for each dataset in 10-fold cross-validation for 
patients in heart failure. It shows a consistent pattern over all the 10 datasets. Interpretation of the 
values (the 33 QoL questions) on the x-axis is provided in Table 2.  
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Table 1: Baseline characteristics by patient groups: patients with HFrEF (LVEF <40% or LVI>Mild), 
patients with HFnEF (LVEF >=40% or LVI<=Mild but NT-proBNP>400ng/L) and patients with no 
HF (LVI<=Mild and NT-proBNP<=400ng/L) 
 
Missing 
values 
                                        HF 
                                  (n = 626) 
 
HF 
(n = 626) 
 
No HF 
(n = 405) 
 
P-value 
 HFrEF  
(n = 377) 
HFnEF 
(n = 249) 
p-
value 
Age (years) 0 69 (11) 74 (9) <0.001 71 (10) 67 (10) <0.001 
Men (%) 0 77% 54% <0.001 65% 233 (58%) 0.001 
IHD (%) 0 64% 39% <0.001 54% 159 (39%) <0.001 
Diabetes (%) 131 19% 21% 0.461 20% 50 (14%) 0.037 
BMI (kg/m
2
) 0 27.1 (24.4-30.3) 27.4 (24.3-31.3) 0.336 27.2 (24.3-30.8) 29.0 (26.1-32.7) <0.001 
COPD (%) 0 7% 10% 0.170 8% 6% 0.395 
AF (%)  0 17% 43% <0.001 27.3% 1% <0.001 
QRS width (msec) 41 112 (98-142) 96 (86-110) <0.001 104 (92-126) 92 (82-101) <0.001 
LVI > Mild (%) 0 100% 0 <0.001 60% 0 <0.001 
Left atrial dimension (cm) 0 4.4(4.0-4.9) 4.2 (3.9-4.9) 0.637 4.3 (3.9-4.9) 3.8 (3.4-4.1) <0.001 
MR> mild  (%)  106 125(35%) 58(25%) 0.013 31% 2% <0.001 
NT-proBNP (ng/L) 0 1592 (652-3718) 1194 (728-2338) 0.079 1389 (678-3049) 127 (68-212) <0.001 
NT-proBNP(ng/L) in 
sinus rhythm 
0 1135(493-2925) 1044(639-1880) 0.931 1104(566-2558) 120(68-211) <0.001 
Sodium (mmol/L) 0 140 (137-141) 140 (137-141) 0.663 140 (137-141) 140 (138-141) <0.001 
Potassium (mmol/L) 7 4.4 (4.1-4.7) 4.4 (4.0-4.8) 0.466 4.4 (4.1-4.7) 4.3 (4.0-4.6) 0.001 
Urea (mmol/L) 0 6.7 (5.3-9.6) 6.8 (5.2-9.4) 0.607 6.8 (5.3-9.5) 5.3(4.3-6.5) <0.001 
Creatinine (umol/L) 0 107 (89-135) 103 (87-129) 0.126 106 (87-132) 88(77-101) <0.001 
eGFR(ml/min/1.73m
2
) 8 61 (45-73) 57 (45-72) 0.166 59 (45-72) 72 (61-83) <0.001 
Hb (g/dL) 0 13.7 (12.4-14.7) 13.2 (11.8-14.3) 0.002 13.5 (12.3-14.5) 14.1 (13.2-15.0) <0.001 
Loop diuretics (%) 19 74% 67% 0.045 71% 32% <0.001 
ACEi (%) 19 73% 54% <0.001 66% 40% <0.001 
ARB (%) 19 7% 7% 0.999 7% 6% 0.630 
BB (%) 19 56% 48% 0.035 53% 39% <0.001 
Digoxin (%) 19 16% 29% <0.001 21% 2% <0.001 
Spironolactone (%) 19 23% 10% <0.001 18% 2% <0.001 
*LVI: left ventricular impairment; IHD: ischemic heart disease; BMI: body mass index; Hb: haemoglobin; BB: beta 
blocker 
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 Table 2.1*: The distributions of the responses to QoL questions for different patient groups 
(Each cell represents the percentage of all patients for that group. The explanation of the 
abbreviated terms in the left column is described in the footnote to the table). 
 Group No Very 
little 
Little Some A lot Very much N 
SoA 
HFrEF 47.5 10.3 10.3 16.2 11.7 4.0 377 
HFnEF 38.6 6.8 12.9 18.9 12.4 10.4 249 
No HF 48.9 10.9 6.2 16.5 12.8 4.7 405 
SoB at rest 
HFrEF 44.3 14.1 10.9 18.6 9.0 3.2 377 
HFnEF 48.2 16.1 9.6 16.9 7.2 2.0 249 
No HF 55.6 11.1 13.8 14.8 4.4 0.2 405 
SoB at night 
HFrEF 52.3 13.0 9.5 14.3 5.6 5.3 377 
HFnEF 56.6 14.5 6.8 14.1 4.4 3.6 249 
No HF 71.1 9.1 7.7 8.6 3.2 0.2 405 
SoB during 
normal 
activity 
HFrEF 20.2 7.7 13.0 24.4 21.2 13.5 377 
HFnEF 27.7 8.8 9.2 17.3 22.1 14.9 249 
No HF 35.1 11.1 9.1 23.5 13.6 7.7 405 
Fatigue at rest 
HFrEF 39.0 13.3 15.6 16.7 9.5 5.8 377 
HFnEF 40.2 14.1 14.9 19.7 8.0 3.2 249 
No HF 51.1 12.3 11.1 17.0 6.7 1.7 405 
Fatigue during 
daily activity 
HFrEF 22.5 13.5 15.4 21.8 18.0 8.8 377 
HFnEF 28.5 12.9 7.2 23.7 18.5 9.2 249 
No HF 35.1 14.8 13.1 20.7 10.1 6.2 405 
Loss of  
appetite 
HFrEF 54.6 11.1 10.1 12.5 7.2 4.5 377 
HFnEF 54.6 8.8 12.0 12.9 7.2 4.4 249 
No HF 75.3 6.7 7.2 8.4 2.0 0.5 405 
Anxiety 
HFrEF 41.1 12.7 13.0 16.2 11.4 5.6 377 
HFnEF 41.8 11.6 14.1 19.7 8.0 4.8 249 
No HF 42.0 14.6 14.6 16.3 9.6 3.0 405 
Depression 
HFrEF 54.4 9.8 14.3 14.1 5.8 1.6 377 
HFnEF 61.8 14.5 7.6 9.6 4.8 1.6 249 
No HF 63.7 9.9 10.4 10.6 3.0 2.5 405 
Decreased 
concentration 
HFrEF 47.2 11.9 16.2 14.6 6.4 3.7 377 
HFnEF 50.6 13.7 16.1 13.7 5.6 0.4 249 
No HF 52.6 12.3 14.1 13.8 6.4 0.7 405 
Stress 
HFrEF 45.6 14.9 14.6 14.6 6.6 3.7 377 
HFnEF 48.2 14.5 13.3 17.3 5.2 1.6 249 
No HF 45.9 12.8 12.3 19.5 6.9 2.5 405 
Insomnia 
HFrEF 43.2 10.3 10.1 16.4 10.1 9.8 377 
HFnEF 46.6 10.4 9.2 16.1 10.0 7.6 249 
No HF 47.9 9.1 11.9 14.8 10.6 5.7 405 
Waking early 
HFrEF 29.4 11.4 13.8 19.1 16.7 9.5 377 
HFnEF 28.9 15.7 14.1 14.9 16.5 10.0 249 
No HF 31.4 13.6 15.1 17.8 15.6 6.7 405 
Lack of  
refreshing 
sleep 
HFrEF 36.9 8.8 12.7 18.6 14.1 9.0 377 
HFnEF 36.1 10.8 11.2 21.7 11.6 8.4 249 
No HF 36.8 9.4 12.3 22.2 12.8 6.4 405 
Reduction in 
daily activity 
HFrEF 25.7 10.1 10.3 22.3 15.1 16.4 377 
HFnEF 27.7 8.8 11.2 19.3 20.5 12.4 249 
No HF 41.5 11.4 10.4 16.8 11.1 8.9 405 
Reduced 
enthusiasm for 
hobbies 
HFrEF 22.3 10.3 8.0 16.4 19.1 23.9 377 
HFnEF 31.7 7.6 7.2 10.4 22.9 20.1 249 
No HF 37.0 7.9 10.4 16.3 15.6 12.8 405 
Table 2
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Friends down 
HFrEF 56.5 10.1 8.8 15.9 4.5 4.2 377 
HFnEF 52.6 12.0 15.3 11.2 4.8 4.0 249 
No HF 70.1 8.6 7.9 7.9 3.5 2.0 405 
 
Loss of control 
HFrEF 44.3 10.3 13.3 15.1 8.5 8.5 377 
HFnEF 49.4 9.2 14.5 12.9 8.4 5.6 249 
No HF 58.3 7.4 13.1 11.4 5.4 4.4 405 
 
Lonely 
HFrEF 60.2 10.3 9.8 9.5 4.5 5.6 377 
HFnEF 60.6 8.8 12.4 11.2 4.0 2.8 249 
No HF 74.8 4.0 8.6 6.7 2.7 3.2 405 
 
Burden 
HFrEF 50.9 10.3 11.9 14.3 6.9 5.6 377 
HFnEF 55.0 9.2 10.8 13.7 6.0 5.2 249 
No HF 69.4 6.7 7.9 10.6 3.2 2.2 405 
 
Loss of  
Memory 
HFrEF 40.8 14.9 15.6 15.6 7.7 5.3 377 
HFnEF 43.0 13.3 20.9 14.9 5.6 2.4 249 
No HF 40.5 16.3 19.3 17.8 3.5 2.7 405 
 
Chest pain 
at rest 
HFrEF 63.4 12.2 8.0 11.7 3.4 1.3 377 
HFnEF 69.5 8.8 8.8 10.4 2.4 0 249 
No HF 61.2 13.8 9.9 11.4 3.2 0.5 405 
Chest pain at 
Daily activity 
HFrEF 54.6 10.1 12.5 13.0 5.3 4.5 377 
HFnEF 58.6 9.2 10.4 15.7 4.8 1.2 249 
No HF 50.9 16.5 12.1 13.6 5.4 1.5 405 
 
Dizziness 
HFrEF 47.7 14.1 12.7 14.1 8.5 2.9 377 
HFnEF 50.2 11.2 14.5 18.5 4.4 1.2 249 
No HF 56.3 10.1 15.1 13.3 3.5 1.7 405 
 
Falls 
HFrEF 81.2 6.1 5.3 5.6 1.9 0 377 
HFnEF 83.1 8.0 4.0 3.2 1.6 0 249 
No HF 88.4 3.7 2.5 4.0 1.0 0.5 405 
 
Cough 
HFrEF 39.3 13.0 14.1 19.9 9.3 4.5 377 
HFnEF 43.0 12.9 13.7 20.1 6.0 4.4 249 
No HF 44.9 12.1 12.3 14.8 11.6 4.2 405 
 
Wheeze 
HFrEF 43.5 11.4 15.6 15.4 9.8 4.2 377 
HFnEF 47.4 11.6 14.5 18.5 6.0 2.0 249 
No HF 50.1 10.1 12.8 17.5 7.4 2.0 405 
 
Muscles & 
Joints 
HFrEF 27.1 10.9 15.4 22.5 12.7 11.4 377 
HFnEF 23.3 9.6 10.4 25.7 18.5 12.4 249 
No HF 21.0 9.9 10.4 28.1 19.8 10.9 405 
 
Indigestion 
HFrEF 56.5 11.9 8.5 14.3 6.6 2.1 377 
HFnEF 55.0 10.0 10.0 15.7 6.8 2.4 249 
No HF 50.6 11.9 10.4 16.3 6.4 4.4 405 
Have to rest 
During the day 
HFrEF 17.8 10.1 17.5 24.4 12.6 5.0 377 
HFnEF 18.5 10.4 16.5 24.1 12.1 6.4 249 
No HF 26.4 10.9 19.0 23.2 8.9 2.7 405 
Make you eat 
less of food  
you like 
HFrEF 46.4 8.8 9.3 17.2 6.5 5.3 377 
HFnEF 46.6 6.0 11.6 16.9 5.8 7.2 249 
No HF 63.0 7.9 5.9 14.1 3.2 2.7 405 
Going places 
away from 
home difficult 
HFrEF 48.0 6.4 9.5 9.8 9.7 6.9 377 
HFnEF 42.2 5.6 8.8 10.8 11.3 10.0 249 
No HF 65.4 4.4 7.2 8.4 5.7 3.2 405 
Making you 
stay in 
Hospital 
HFrEF 60.5 6.4 6.9 8.8 2.7 12.2 377 
HFnEF 59.8 6.0 4.4 7.6 4.2 13.7 249 
No HF 80.2 2.0 3.2 3.0 1.1 9.4 405 
 
 
The full descriptive terms of the abbreviation of the questions are as follows (the questions are: how much did 
any the following (1-33) affect you in the last month?): 
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1.SoA: Swelling of ankles or legs;  
2. SoB at rest: Breathlessness while sitting at rest; 
3. SoB at night: Breathlessness waking you from sleep; 
4. SoB normal activity: Breathless that limits your ability to do normal daily activities; 
5. Fatigue at rest 
6. Fatigue daily activity: Fatigue that limits your ability to do normal daily activities  
7. Loss of appetite 
8. Anxiety:Anxiety or worry  
9. Depression 
10. Concentration:Loss of concentration  
11. Stress 
12. Insomnia:Inability to get to sleep  
13. Waking:Waking up in the night and having difficulty getting back to sleep  
14. Lack of refreshing sleep 
15. Daily activity down:Inability to do normal daily activities due to your health  
16. Hobbies down:Inability to do hobbies or sports due to your health  
17. Friends down:Inability to enjoy the company of friends & family due to your health  
18*. Work down: Inability to work due to your health  
19*. Side effects: Side-effects that you think might be due to your treatment  
20*. Sex: Difficulties with sexual function  
21*. Drug cost: Costs of medicines or medical care  
22. Loss of control:Feelings of loss of control over your life  
23. Lonely:Feelings of loneliness  
24. Burden:Feelings that you are a burden to others  
25. Loss of memory:Loss of memory for names or recent events  
26. Chest pain at rest: Chest pains (inc. Angina) occurring while sitting at rest  
27. Chest pain daily activity:Chest pains (inc. Angina) occurring while doing normal daily activates  
28. Dizziness 
29. Falls:Falls or Blackouts  
30. Cough 
31. Wheeze 
32. Muscles:Aching muscles or joints  
33. Indigestion:Indigestion or dyspepsia  
34. Have to rest during the day 
35. Make you eat less of food you like 
36. Going places away from home difficult 
37. Making you stay in hospital more often 
 
Note that the above 4 questions (*) were not included in the analysis due to too many missing values. A copy of 
the survey is available in Appendix. 
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Table 2.2: The distributions of the responses of overall QoL questions for different patient 
groups (Each cell represents the percentage of total patients of each group.  
  Very 
good 
Good Quite 
good 
average Quite 
poor 
Poor Very 
poor 
N 
 
Overall health 
HFrEF 3.4 10.9 16.4 34.2 14.1 13.5 7.4 377 
HFnEF 3.2 15.7 18.9 30.1 10.0 16.9 5.2 249 
No HF 7.9 17.5 19.8 30.9 12.3 10.4 1.2 405 
 
Overall QoL 
HFrEF 7.2 17.8 19.6 29.7 11.1 9.0 5.6 377 
HFnEF 8.0 19.7 18.1 27.3 8.8 13.3 4.8 249 
No HF 14.6 24.4 20.0 24.9 6.2 8.1 1.7 405 
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Table 3: Factor loadings after rotation for each symptom cluster in patients with HF (626 patients) and without HF (405 patients) 
 HF No HF 
 Bre
a
th
le
s
s
n
e
s
s
 
P
s
y
c
h
o
lo
g
ic
a
l 
d
is
tre
s
s
 
S
le
e
p
 q
u
a
lity
 
F
ra
ilty
 
C
o
g
n
itiv
e
 / 
P
s
y
c
h
o
m
o
to
r 
fu
n
c
tio
n
 
C
o
u
g
h
 
C
h
e
s
t p
a
in
 
B
re
a
th
le
s
s
n
e
s
s
 
C
h
e
s
t p
a
in
/ 
B
re
a
th
le
s
s
n
e
s
s
 
P
s
y
c
h
o
lo
g
ic
a
l 
d
is
tre
s
s
 
S
le
e
p
 q
u
a
lity
 
F
ra
ilty
 
C
o
g
n
itiv
e
   / 
P
s
y
c
h
o
m
o
to
r 
fu
n
c
tio
n
 
R
e
s
p
ira
to
ry
 
s
y
m
p
to
m
s
 
F
a
lls
 
SoA -- -- -- -- -- -- --        0.43 
SoB at rest 0.49        0.64       
SoB at night      0.45   0.60       
SoB normal activity 0.75       0.70 0.42       
Fatigue at rest 0.52       0.47 0.52       
Fatigue on daily activity 0.76       0.72        
Loss of appetite   0.42         0.44    
Anxiety  0.77        0.84      
Depression  0.81        0.79      
Concentration  0.51   0.55        0.62   
Stress  0.81        0.80      
Insomnia   0.82        0.82     
Waking   0.83        0.88     
Lack of refreshing sleep   0.75        0.78     
Daily activity down 0.78       0.79        
Hobbies down 0.73       0.72        
Friends down 0.48              0.42 
Loss of control 0.52 0.45      0.44        
Lonely  0.64        0.60      
Burden 0.41 0.53        0.41     0.41 
Loss of memory     0.71        0.74   
Table 3
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Chest pain at rest       0.84  0.79       
Chest pain at daily activity       0.83  0.75       
Dizziness     0.60    0.40    0.42  0.40 
Falls     0.62          0.74 
Cough      0.84        0.81  
Wheeze      0.76        0.79  
Muscles     0.43   -- -- -- -- -- -- -- -- 
Indigestion -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
Have to rest during the 
day 
0.41   0.58    0.52    0.45    
Make you eat less of food 
you like 
   0.74        0.77    
Going places away from 
home difficult 
   0.70    0.40    0.64    
Making you stay in 
hospital 
   0.78        0.72    
Variance explained (%) 
14.51 12.60 9.20 8.35 7.52 6.25 6.14 13.02 10.52 10.00 8.33 7.04 6.09 5.57 5.53 
Cumulative variance 
explained (%) 
14.51 27.11 36.31 44.66 52.18 58.43 64.57 13.02 23.54 33.55 41.88 48.91 55.01 60.58 66.11 
 Cronbach's alpha 0.89 0.83 0.83 0.79 0.62 0.68 0.84 0.88 0.83 0.84 0.89 0.67 0.73 0.75 0.64 
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Table 4.1: The relationships between overall health, overall QoL, a summary QoL score, a 
summary symptom cluster scores and NYHA class for patients with HF (626 patients) / 
without HF (405 patients) respectively  
Overall health Overall QoL 
Sum score 
QoL 
Sum symptom 
cluster score NYHA class 
Overall health 1.00 
Overall QoL 
0.730/0.759 
(p<0.001) 
1.00 
Sum score of QoL 
0.661/0.667 
(p<0.001) 
0.658/0.642 
(p<0.001) 
1.00 
Sum symptom 
cluster score 
0.614/0.678 
(p<0.001) 
0.602/0.654 
(p<0.001) 
0.964/0.954 
(p<0.001) 1.00 
NYHA class 
0.312/0.393 
(p<0.001) 
0.322/0.404 
(p<0.001) 
0.435/0.463 
(p<0.001) 
0.410/0.389 
(p<0.001) 1.00 
*Correlation is significant at the 0.01 level (2-tailed) use the Spearman's rank correlation test.
Table 4.2: The relationships between each individual symptom cluster scores and overall 
health and overall QoL scores and NYHA class in patients with HF (626 patients) 
Breathless 
ness 
Psychological 
distress 
Sleep 
quality 
Frailty 
Cognitive / 
psychomotor 
function 
Chest 
pain 
Respiratory 
symptoms 
Overall health 
0.50 
(p<0.001) 
0.28 
(p<0.001) 
0.17 
(p<0.001) 
0.24 
(p<0.001) 
0.17 
(p<0.001) 
0.19 
(p<0.001) 
0.05 
(p=0.22) 
Overall QoL 
0.47 
(p<0.001) 
0.32 
(p<0.001) 
0.15 
(p<0.001) 
0.26 
(p<0.001) 
0.20 
(p<0.001) 
0.12 
(p=0.004) 
0.03 
(p=0.40) 
NYHA class 
0.32 
(p<0.001) 
0.12 
(p=0.002) 
0.21 
(p<0.001) 
0.17 
(p<0.001) 
0.02 
(p=0.612) 
0.22 
(p<0.001) 
0.01 
(p=0.728) 
Table 4
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